

Short Communication

Glycogen synthase kinase-3 β (GSK-3 β) inhibitors AR-A014418 and B6B30 prevent human immunodeficiency virus-mediated neurotoxicity in primary human neurons

Timothy B. Nguyen,¹ Ginger R. Lucero,¹ Gursharan Chana,¹ Britta J. Hult,¹ Erick T. Tatro,¹ Eliezer Masliah,² Igor Grant,¹ Cristian L. Achim,¹ Ian P. Everall,¹ and the HIV Neurobehavioral Research Group

¹Department of Psychiatry, HIV Neurobehavioral Research Center; and ²Department of Neurosciences, University of California, San Diego, California, USA

Glycogen synthase kinase-3 β (GSK3 β) role in human immunodeficiency virus (HIV)-associated neurodegeneration has been evidenced by previous investigations. In this study, we investigated the specificity of two GSK3 β -specific inhibitors, AR-A014418 (A) and B6B30 (B) to prevent direct neurotoxicity in primary human neurons exposed to HIV (BaL). Neurons were exposed to HIV (500 pg/ml) for 12-h and 6-day periods in the presence and absence of A (1 μ M, 100 nM, 10 nM) and B (50 nM, 5 nM, 500 pM) to investigate acute and ongoing mechanisms of HIV neurotoxicity. Using an lactate dehydrogenase (LDH) assay to assess cytotoxicity, we observed a significant neurotoxic effect of HIV from control values ($P < .01$) that was not restored via coexposures of all concentrations of A and B. Additionally, no change in LDH levels were observed after 6 days. However, activity of the acute proapoptotic markers caspases 3 and 7 using a luminescence assay were measured and found to be increased by exposure to HIV (BaL) compared to controls ($P = .022$). This effect was ameliorated via coexposure to all concentrations of A and 50 nM B after 12 h ($P < .01$) and to all concentrations of A and B after 6 days ($P < .01$). Overall, the results from this study provide further evidence for the ability of GSK3 β inhibition to be neuroprotective against HIV-associated neurotoxicity by reducing HIV associated procaspase induction. These data support a role for GSK3 β as a potential therapeutic target and may have important clinical implications for treatment of HIV-associated neurocognitive disorder. *Journal of NeuroVirology* (2009) 15, 434–438.

Keywords: AR-A014418; B6B30; caspase; GSK3 β ; HIV; neurotoxicity

Introduction

Human immunodeficiency virus (HIV) is a neurotropic virus that results in a spectrum of inflammatory related brain changes, including HIV encephalitis and HIV leukoencephalopathy (Budka *et al*, 1991), accompanied by reductions in synaptodendritic markers and neuronal loss

(Everall *et al*, 1991, 1993, 1999; Masliah *et al*, 1997). Clinically, both inflammatory and synaptodendritic degeneration seen postmortem correlate with the severity of HIV-associated neurocognitive disorder (HAND) seen prior to death (Cherner *et al*, 2002; Everall *et al*, 1999; Masliah *et al*, 1997). Despite the introduction of highly active retroviral treatment (HAART), HAND still remains prominent within the HIV-infected community (Clifford, 2008; Nath *et al*, 2008). Therefore, although antiretrovirals (ARVs) substantially reduce viral load, their effect on reducing symptoms of HAND is less evident. The pathophysiological process that results in HIV

Address correspondence to Dr Ian Paul Everall, Department of Psychiatry, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0603, USA. E-mail: ieverall@ucsd.edu

Received 13 January 2009; revised 8 June 2009; accepted 26 June 2009.

neurodegeneration is complex and mediated by both direct toxic effects of HIV viral proteins as well as indirect toxic effects via release of proinflammatory cytokines and dysregulation of other processes, including trophic factors. Previously, we have noted that synaptodendritic damage is related to brain viral burden (Everall *et al*, 1999; Masliah *et al*, 1997) and that the severity of neurodegeneration can be ameliorated when the host brain neurons can maintain expression of the neurotrophic agent fibroblast growth factor-1 (FGF1) (Everall *et al*, 2001). In further experiments, we noted that the intracellular signaling pathway by which FGF1 mediates this neuroprotection involved the inhibition of glycogen synthase kinase-3 β (GSK3 β). This was evidenced via blockade of the phosphatidylinositol 3-kinase (PI3)/Akt pathway by LY294002, a pathway that is an upstream regulator of GSK3 β (Sagara *et al*, 2001). GSK3 β in the nervous system has been associated with neuronal migration, axonal remodeling, and synaptic plasticity (Packard *et al*, 2003). In support of a neuroprotective capacity of GSK3 β inhibition, up-regulation of GSK3 β has been observed following exposure of cerebellar granule neurons to HIV-tat and down-stream mediator platelet-activating factor (PAF), resulting in apoptosis (Maggirwar *et al*, 1999; Tong *et al*, 2001).

In relation to the treatment of HAND, the mood stabilizers lithium and sodium valproate have both been shown to inhibit GSK3 β activity (Klein and Melton, 1996; Rowe *et al*, 2007). Our group noted that that the HIV envelope glycoprotein (gp120) is capable of causing direct toxicity in primary human neuronal cultures (Everall *et al*, 2001) and that lithium prevented gp120-associated neurotoxicity (Everall *et al*, 2002), whereas Dou *et al* (Dou *et al*, 2003; Dou *et al*, 2005) noted a similar neuroprotective effect for both lithium and sodium valproate. Clinically, Letendre *et al* (Letendre *et al*, 2006) carried out a single-arm open-label pilot study of lithium 300 mg daily for 12 weeks in eight HIV-infected individuals with documented HAND. Lithium was found to result in improved neuropsychological performance in all individuals. Similarly in a 10-week trial of 16 HIV-infected individuals, in which 6 had no cognitive impairment, administration of 250 mg bid (twice daily) of sodium valproate resulted in a trend for improved neuropsychological performance and related to a significant increase in *N*-acetylaspartate activity in frontal white matter as an indicator of improved activity (Schifitto *et al*, 2006). As both sodium valproate and lithium can have multiple effects on several intracellular signaling pathways, it is possible that other pathways not involving GSK3 β be involved in their therapeutic action. Recently, it has been observed that lithium and sodium valproate work synergistically to prevent glutamate induced neurotoxicity in cerebellar granule cells, an effect that could also be achieved via the transfection of cells with small interfering RNA (siRNA) to GSK3 β (Leng *et al*, 2008).

This study highlights the potential of these compounds in blocking GSK3 β and preventing neurodegenerative effects that may be advantageous in alleviating symptoms of HAND. Therefore, the aim of this investigation was to further characterize how GSK3 β -specific inhibition may mediate neuroprotection resulting from direct HIV-mediated neurotoxicity *in vitro*. We investigated the ability of two recently developed specific GSK3 β inhibitors, AR-A014418 (A) and BIO-(2'Z,3'E)-6-bromoindirubin-3'-oxime (B6B3O) (B), in ameliorating HIV (BaL)-mediated neurotoxicity, and assessed acute mechanisms for this toxicity via measurement of caspase activation and postnecrotic measurements of lactate dehydrogenase (LDH) released from primary human neurons exposed to HIV (BaL) viral supernatants taken from human primary macrophages.

Results

LDH

A significant increase ($P < .01$) in LDH was observed in primary human neurons following 12-h exposure to 20% conditioned HIV macrophage supernatants (equivalent to 500 pg/ml), demonstrating toxicity of HIV to primary human neurons. This acute effect was not ameliorated with coexposure of either compound A or B, which were also elevated from control values ($P < .01$) and not significantly different from HIV alone ($P > .10$). No significant differences in LDH values between conditions were seen in 6-day exposures.

12-Hour HIV exposure and caspase 3,7

Exposure of human primary neurons to 20% conditioned HIV macrophage supernatants (equivalent to 500pg/ml) produced a 34% increase in caspase 3,7 activity and compared to controls ($P = .022$). Coexposure of primary human neurons with HIV and compound A at 1 μ M, 100 nM, and 10 nM produced 38%, 62%, and 58% decreases in caspase 3,7 activity, respectively, when compared to HIV alone ($P < .01$). Although all concentrations of A reduced caspase 3,7 activity below even that for controls, these effects were not significant. Coexposure of neurons with HIV and compound B at 50 nM produced a 52% decrease in caspase 3,7 activity when compared to HIV alone ($P < .01$). Although other concentrations of B decreased activity of caspase 3,7 from HIV alone, these effects did not reach significance. Figure 1 below illustrates these results.

6-Day HIV exposure and caspase 3,7

Exposure of primary human neurons to 20% conditioned HIV macrophage supernatants (equivalent to 500 pg/ml) for a period of 6 days produced a 24% increase in caspase 3,7 activity compared to controls ($P < .01$). Coexposure of primary human neurons with HIV and compound A at 1 μ M, 100 nM, and 10 nM




Figure 1 Twelve-hour caspase 3/7 activity of HIV (BaL) (500 pg/ml)-exposed human primary neurons in the presence and absence of GSK3 β inhibitors A and B. Human primary neurons were incubated for 12 h in the presence and absence of HIV (BaL) at 500 pg/ml with and without A (1 μ M, 100 nM, 10 nM) and B (500 pM, 5 nM, and 50 nM). Exposure to HIV (BaL) resulted in a significant increase in caspase 3/7 activity ($P=.022$). Coexposure of HIV with all concentrations of A significantly decreased caspase 3,7 activity from HIV alone ($P<.01$). Coexposure of compound B at 50 nM also produced significant decreases in caspase 3,7 activity ($P<.01$). Data represented are % change in caspase 3,7 activity from controls. *Significant at $P<.05$.

produced 29%, 25%, and 27% decreases in caspase 3,7 activity, respectively, when compared to HIV alone ($P<.01$). Coexposure of primary human neurons with HIV and compound B at 50 nM, 5 nM, and 500 pM produced 27%, 33%, and 39% decreases in caspase 3,7 activity, respectively, when compared to HIV alone ($P<.001$). Figure 2 below illustrates these results.

Discussion

In this study we observed the ability of the specific GSK3 β inhibitors AR-A014418 (1 μ M, 500 nM, 50 nM) and B6B3O (50 nM, 5 nM, 500 pM) to significantly reduce HIV-induced caspase 3/7 activity back to control values at both 12 hours and 6 days of exposure. Whereas we noted that these two inhibitors were not associated with neurotoxicity at IC₅₀ concentrations or above, we observed reduced HIV-mediated caspase activation, insignificantly different from control values, at both log₁₀ order concentrations above and below IC₅₀. This strongly implies that GSK3 β inhibitors may be effective in continually and selectively mitigating proapoptotic HIV-induced caspase cascades (Gwenn *et al*, 2002). However, it should be noted that LDH levels remained significantly elevated in HIV at 12 hours without amelioration by GSK3 β inhibitors. Furthermore,




Figure 2 Six-day caspase 3/7 activity of HIV (BaL) (500 pg/ml)-exposed human primary neurons in the presence and absence of GSK3 β inhibitors A and B. Human primary neurons were incubated for 6 days in the presence and absence of HIV (BaL) at 500 pg/ml with and without A (1 μ M, 100 nM, 10 nM) and B (500 pM, 5 nM and 50 nM). Exposure to HIV (BaL) resulted in a significant increase in caspase 3/7 activity ($P<.01$). Coexposure of HIV with all concentrations of A and B significantly decreased caspase 3,7 activity from HIV alone ($P<.01$). Data represented are % change in caspase 3,7 activity from controls. *Significant at $P<.05$.

LDH levels were not significantly elevated among any exposure condition at 6 days. Although we acknowledge that elevated LDH levels at 12 hours could be an artifact from using macrophage supernatant, other acute HIV-mediated neurodegenerative processes may be at work. This implies that GSK3 β inhibitors may be effective in selectively mitigating proapoptotic HIV-induced caspase cascades (Gwenn *et al*, 2002), but not other possible acute neurodegenerative factors caused by HIV such as oxidative stress (Kaul *et al*, 2001). Although caspase 3/7 and supernatant LDH levels did not correlate at 6 days, it has been shown that activation of caspases do not commit neuronal cells to immediate cell death that would be detected by the LDH assay but may induce a protracted or reversible form of apoptosis (Zhang *et al*, 2000).

Our findings indicate that acute and long-term HIV-mediated neurotoxicity via induction of proapoptotic cascades can be abrogated by inhibition of GSK3 β . However, because LDH levels measure the end point of cell death, the discrepancy between caspase and LDH results suggest that further study is warranted on other distinct pathways of neurodegeneration. It is possible that other viral proteins such as gp120, tat, and nef, which are known to be neurotoxic (Bansal *et al*, 2000; Gurwell *et al*, 2001;

Trillo-Pazos *et al*, 2000), may also contribute to the activation of caspase 3/7 that we observed in HIV (BaL) exposures as well as cytokines and proinflammatory markers released by microglia. Preventing HIV-mediated neurotoxicity and neurodegenerative effects have implications in alleviating symptoms of HIV within the brain and treatment of HAND. This is consistent with a growing body of *in vitro* and clinical literature demonstrating the neuroprotective effects of inhibiting the GSK3 β pathway with therapeutic agents such as lithium and sodium valproate (Dou *et al*, 2003,2005; Everall *et al*, 2002; Letendre *et al*, 2006). AR-A014418 neuroprotection demonstrated in our study is consistent with a previous finding also demonstrating this effect in neuroblastoma N2A cells exposed to β -amyloid neurodegenerative effects (Bhat *et al*, 2003). Our utilization of specific GSK3 β inhibitors to demonstrate neuroprotective effects against direct HIV-induced neurotoxicity contribute to the rational of developing therapeutic agents that target GSK3 β activity (Cohen and Goedert, 2004; Dewhurst *et al*, 2007) and may provide a novel approach to preventing the development and progress of HAND in individuals stabilized on ARVs (Clifford, 2008; Nath *et al*, 2008).

Materials and methods

Establishment of primary human neuronal cultures

Human primary neuronal cultures were prepared as previously described from human fetal brain tissue, 14 to 18 weeks' gestation, collected from consenting patients undergoing terminations without any clinical identifiers (Advanced Bioscience Resources, CA, USA) (Trillo-Pazos *et al*, 2004). Cultures were maintained for a period of 30 days prior to experimentation. This time period corresponds to the beginning of *N*-methyl-d-aspartate (NMDA) receptor expression in these cultures and as such is representative of a functionally mature phenotype (Mattson *et al*, 1991).

12-Hour HIV exposure

Human primary neurons were incubated in the presence and absence of 20% conditioned HIV (BaL) macrophage supernatants (equivalent to

500 pg/ml) with and without GSK3 β inhibitors AR-A014418 (A) (1 μ M, 100 nM, 10 nM) and B6B3O (B) (50 nM, 5 nM, 500 pM) (both obtained from Sigma Aldrich, USA). IC₅₀ values have been previously determined to be 100 nM for A and 5 nM for B from dose-response curves of inhibitor and substrate affinity binding by nuclear magnetic resonance spectroscopy (Meijer *et al*, 2004). Concentrations used were shown to be nontoxic to neuronal cultures in a prior 6-day exposure period measured using a LDH cytotoxicity assay (CytoTox96, Promega, USA), which measures extracellular leakage of this enzyme when the cell membrane is compromised. HIV (BaL) is a macrophage-, monocyte-, and CD4+ T cell-tropic HIV-1 strain obtained from the NIH AIDS Research and Reference Reagent Program (catalogue number 510). After 12 h, cells were scraped and lysed using the the caspase-glo 3/7 luminescence assay (Promega) and levels of caspases 3 and 7 were measured as an early indicator of neurodegenerative changes related to apoptosis. Results were expressed as arbitrary relative luminescence units and normalized into percent changes of caspase luminescence from controls. LDH levels from cellular supernatant were also measured after 12 h and normalized into percent change of LDH released from controls.

6-Day HIV exposure

Exposure of human primary neurons to HIV with and without A and B were repeated as above. Media, including HIV and A and B, were changed once on day 3. Caspase 3/7 and LDH measurements were repeated after 6 days.

Statistical Analysis

An one-way analysis of variance (ANOVA) was performed on the data to compare caspase 3/7 activation and LDH levels between control and treatment groups using a Tukey-HSD (highly significant difference) post hoc analysis for multiple comparisons.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

References

- Bansal AK, Mactutus CF, Nath A, Maragos W, Hauser KF, Booze RM (2000). Neurotoxicity of HIV-1 proteins gp120 and Tat in the rat striatum. *Brain Res* **879**: 42–49.
- Bhat R, Xue Y, Berg S, Hellberg S, Ormo M, Nilsson Y, Radesater AC, Jerning E, Markgren PO, Borgegard T, Nylof M, Gimenez-Cassina A, Hernandez F, Lucas JJ, Diaz-Nido J, Avila J (2003). Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. *J Biol Chem* **278**: 45937–45945.
- Budka H, Wiley CA, Kleihues P, Artigas J, Asbury AK, Cho ES, Cornblath DR, Dal Canto MC, DeGirolami U, Dickson D (1991). HIV-associated disease of the nervous system: review of nomenclature and proposal for neuropathology-based terminology. *Brain Pathol* **1**: 143–152.
- Cherner M, Masliah E, Ellis RJ, Marcotte TD, Moore DJ, Grant I, Heaton RK (2002). Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. *Neurology* **59**: 1563–1567.
- Clifford DB (2008). HIV-associated neurocognitive disease continues in the antiretroviral era. *Top HIV Med* **16**: 94–98.

- Cohen P, Goedert M (2004). GSK3 inhibitors: development and therapeutic potential. *Nat Rev Drug Discov* **3**: 479–487.
- Dewhurst S, Maggirwar SB, Schifitto G, Gendelman HE, Gelbard HA (2007). Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDS. *J Neuroimmune Pharmacol* **2**: 93–96.
- Dou H, Birusingh K, Faraci J, Gorantla S, Poluektova LY, Maggirwar SB, Dewhurst S, Gelbard HA, Gendelman HE (2003). Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. *J Neurosci* **23**: 9162–9170.
- Dou H, Ellison B, Bradley J, Kasiyanov A, Poluektova LY, Xiong H, Maggirwar S, Dewhurst S, Gelbard HA, Gendelman HE (2005). Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis. *J Neurosci* **25**: 8375–8385.
- Everall IP, Bell C, Mallory M, Langford D, Adame A, Rockenstein E, Masliah E (2002). Lithium ameliorates HIV-gp120-mediated neurotoxicity. *Mol Cell Neurosci* **21**: 3: 493–501.
- Everall IP, Heaton RK, Marcotte TD, Ellis RJ, McCutchan JA, Atkinson JH, Grant I, Mallory M, Masliah E (1999). Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HNRC Group. HIV Neurobehavioral Research Center. *Brain Pathol* **9**: 209–217.
- Everall IP, Luthert PJ, Lantos PL (1991). Neuronal loss in the frontal cortex in HIV infection. *Lancet* **337**: 1119–1121.
- Everall IP, Luthert PJ, Lantos PL (1993). Neuronal number and volume alterations in the neocortex of HIV infected individuals. *J Neurol Neurosurg Psychiatry* **56**: 481–486.
- Everall IP, Trillo-Pazos G, Bell C, Mallory M, Sanders V, Masliah E (2001). Amelioration of neurotoxic effects of HIV envelope protein gp120 by fibroblast growth factor: a strategy for neuroprotection. *J Neuropathol Exp Neurol* **60**: 293–301.
- Gurwell JA, Nath A, Sun Q, Zhang J, Martin KM, Chen Y, Hauser KF (2001). Synergistic neurotoxicity of opioids and human immunodeficiency virus-1 Tat protein in striatal neurons in vitro. *Neuroscience* **102**: 3: 555–563.
- Garden G, Budd S, Tsai E, Hanson L, Kaul M, Emilia D, Friedlander R, Yuan J, Masliah E, Lipton S (2002). Caspase cascades in human immunodeficiency virus-associated neurodegeneration. *J Neurosci* **22**: 4015–4024.
- Hashimoto M, Sagara Y, Langford D, Everall IP, Mallory M, Everson A, Digicaylioglu M, Masliah E (2001). Fibroblast growth factor 1 regulates signaling via the glycogen synthase kinase-3beta pathway. Implications for neuroprotection. *J Biol Chem* **277**: 36: 32985–32991.
- Kaul M, Garden G, Lipson SA (2001). Pathways to neuronal injury and apoptosis in HIV-associated dementia. *Nature* **410**: 988–994.
- Klein PS, Melton DA (1996). A molecular mechanism for the effect of lithium on development. *Proc Natl Acad Sci U S A* **93**: 8455–8459.
- Leng Y, Liang MH, Ren M, Marinova Z, Leeds P, Chuang DM (2008). Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. *J Neurosci* **28**: 2576–2588.
- Letendre SL, Woods SP, Ellis RJ, Atkinson JH, Masliah E, van den Brande G, Durelle J, Grant I, Everall I (2006). Lithium improves HIV-associated neurocognitive impairment. *AIDS* **20**: 1885–1888.
- Maggirwar SB, Tong N, Ramirez S, Gelbard HA, Dewhurst S (1999). HIV-1 Tat-mediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated neurotoxicity. *J Neurochem* **73**: 578–586.
- Masliah E, Heaton RK, Marcotte TD, Ellis RJ, Wiley CA, Mallory M, Achim CL, McCutchan JA, Nelson JA, Atkinson JH, Grant I (1997). Dendritic injury is a pathological substrate for Human Immunodeficiency Virus-related cognitive disorders. *Ann Neurol* **42**: 963–972.
- Mattson MP, Wang H, Michaelis EK (1991). Developmental expression, compartmentalization, and possible role in excitotoxicity of a putative NMDA receptor protein in cultured hippocampal neurons. *Brain Res* **565**: 94–108.
- Meijer L, Flajolet M, Greengard P (2004). Pharmacological inhibitors of glycogen synthase kinase 3. *Trends Pharmacol Sci* **25**: 471–480.
- Nath A, Schiess N, Venkatesan A, Rumbaugh J, Sacktor N, McArthur J (2008). Evolution of HIV dementia with HIV infection. *Int Rev Psychiatry* **20**: 25–31.
- Packard M, Mathew D, Budnik V (2003). Wnts and TGF beta in synaptogenesis: old friends signalling at new places. *Nat Rev Neurosci* **4**: 113–120.
- Rowe MK, Wiest C, Chuang DM (2007). GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. *Neurosci Biobehav Rev* **31**: 920–931.
- Schifitto G, Peterson DR, Zhong J, Ni H, Cruttenden K, Gaugh M, Gendelman HE, Boska M, Gelbard H (2006). Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. *Neurology* **66**: 919–921.
- Tong N, Sanchez JF, Maggirwar SB, Ramirez SH, Guo H, Dewhurst S, Gelbard HA (2001). Activation of glycogen synthase kinase 3 beta (GSK-3beta) by platelet activating factor mediates migration and cell death in cerebellar granule neurons. *Eur J Neurosci* **13**: 1913–1922.
- Trillo-Pazos G, Kandaneeratchi A, Eyeson J, King D, Vyakarnam A, Everall I (2004). Infection of stationary human brain aggregates with HIV-1 sf162 and IIIB results in transient neuronal damage and neurotoxicity. *Neuropathol Appl Neurobiol* **30**: 136–147.
- Trillo-Pazos G, McFarlane-Abdulla E, Campbell IC, Pilkington GJ, Everall IP (2000). Recombinant nef HIV-IIIB protein is toxic to human neurons in culture. *Brain Res* **864**: 315–326.
- Zhang Y, Goodyer C, LeBlanc A (2000). Selective and protracted apoptosis in human primary neurons micro-injected with active caspase -3, -6, -7, and -8. *J Neurosci* **20**: 185–200.